 Genprex Inc NASDAQ:GNPX announced Monday the formation of a Clinical Advisory Board CAB to support its oncology and diabetes development programs. Comprised of preeminent clinical specialists, the company said the CAB will lead and advise Genprex as it advances its REQORSA immunogene therapy program, including its Acclaim clinical trials in non-small cell lung cancer, and its preclinical diabetes gene therapy program. 